


Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2018

Rs. in Lakhs


Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2018 (Unaudited)	31.03.2018 (Audited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1	Revenue from Operations	4,452	3,321	2,961	12,530
2	Other Income	130	318	385	3,701
3	Total Income	4,582	3,639	3,346	16,231
4	Expenses				
	Cost of Materials Consumed	546	634	619	3,986
	Cost of Construction	1,427	877	641	3,078
	Changes in Inventories of Finished Goods and WIP	766	532	746	809
	Employee Benefit Expenses	485	622	493	2,074
	Finance Costs	6	3	4	17
	Depreciation and amortisation expense	64	61	123	378
	Other Expenses	403	654	285	1,472
	Total Expenses	3,697	3,382	2,911	11,813
5	Profit Before Tax	885	257	435	4,417
6	Tax Expenses				
	Current Tax	190	54	90	431
	Deferred Tax	20	(41)	11	30
	Short / (Excess) Provision of earlier years	(16)	(222)	-	(222)
7	Net Profit after tax for the Period	691	466	335	4,178
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or Loss	942	430	5	4,443
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(134)	121	(3)	114
9	Total Comprehensive Income for the Period	1,500	1,016	337	8,735
10	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.26	0.17	0.13	1.56



Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2018 (Unaudited)	31.03.2018 (Audited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,955	1,540	1,743	6,636
	b. Real Estate Business	2,498	1,781	1,218	5,893
	Total Income from Operations (Net)	4,452	3,321	2,961	12,530
2	Segement Results (Profit +)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	99	(384)	5	26
	b. Real Estate Business	727	457	163	1,319
	Total	826	72	168	1,346
	Unallocable Income and Expenditure				
	(i) Interest Expense	(6)	(3)	(4)	(17)
	(ii) Dividend Income & Gain on financial asset at Fair Value	33	90	235	2,940
	(iii) Other Income	32	98	37	148
	Total Profit Before Tax	885	257	435	4,417
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	17,456	17,189	19,627	17,189
	b. Real Estate Business	9,294	7,426	6,778	7,426
	c. Unallocated	19,722	27,581	19,453	27,581
	Total	46,473	52,196	45,858	52,196
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	2,457	2,071	3,139	2,071
	b. Real Estate Business	4,575	4,309	4,368	4,309
	c. Unallocated	1,272	947	1,242	947
	Total	8,304	7,328	8,749	7,328

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- Effective 1st April, 2018, the Company has adopted Ind AS 115 using the cumulative effect method. The standard is applied retrospectively to contracts that are not completed as at the date of initial application and the comparative information is not restated. The effect of adoption of the standard did not have any significant impact on the financial statements of the Company.
- During the quarter, the Company completed the Buy-back of 1,02,50,000 Equity Shares of Rs. 2/- each and extinguished the shares bought back on 14th May, 2018.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.



For Alembic Limited

Chirayu Amin
Chairman

Limited Review Report**To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Alembic Limited** ("the Company") for the quarter/three months ended 30th June, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

**Himanshu Kishnadwala**

Partner

Membership No. 37391

Place: Vadodara

Date: 07th August, 2018